Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers

Restriction of iron availability by ferroportin inhibition is a novel approach to treating non‐transfusion‐dependent thalassemia (β‐thalassemia intermedia). This first‐in‐human, Phase I study (https://www.clinicaltrialsregister.eu; EudraCT no. 2017‐003395‐31) assessed the safety, tolerability, pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Richard, Frank, van Lier, Jan Jaap, Roubert, Bernard, Haboubi, Teba, Göhring, Udo‐Michael, Dürrenberger, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916274/
https://www.ncbi.nlm.nih.gov/pubmed/31674058
http://dx.doi.org/10.1002/ajh.25670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916274/
https://www.ncbi.nlm.nih.gov/pubmed/31674058
http://dx.doi.org/10.1002/ajh.25670

Ejemplares similares